A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Clinical trial NCT02249091 · COMPLETED
Trial details
- NCT number
- NCT02249091
- Sponsor
- GSO Global Clinical Research BV
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-01
- Primary completion
- 2018-07-31
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.